CRISPR Therapeutics AG — Director's Dealing 2021

Aug 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-08-06

Reporting Person: TOMSICEK MICHAEL JOHN (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-06	Common Shares	M	25000	$17.75	Acquired	26891	Direct
2021-08-06	Common Shares	S	19011	$138.22	Disposed	7880	Direct
2021-08-06	Common Shares	S	5989	$139.46	Disposed	1891	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-11	Stock Option (Right to Buy)	$17.75	M	25000	Disposed	2027-11-21	Common Shares (25000)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.00 to $138.97, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.06 to $139.69, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F4: This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month.